Cubist Pharmaceuticals Inc.
Description Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. It provides CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also co-promotes DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD). In addition, its development products include Ceftolozane/tazobactam that is in Phase III clinical trials to treat complicated urinary tract infections and complicated intra-abdominal infections. Further, the company is developing ceftolozane/tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additionally, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and CB-625 that is in Phase I clinical studies to treat acute pain and various inflammatory conditions. In addition, the company’s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts. To view the detailed information, you need to SUBSCRIBE with us. |
 |